



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Adress: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,310	05/12/2006	Jorgen Carlsson	102821-202	6946
27267	7590	09/08/2010	EXAMINER	
WIGGIN AND DANA LLP			SWARTZ, RODNEY P	
ATTENTION: PATENT DOCKETING			ART UNIT	PAPER NUMBER
ONE CENTURY TOWER, P.O. BOX 1832			1645	
NEW HAVEN, CT 06508-1832			MAIL DATE	DELIVERY MODE
			09/08/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/563,310	Applicant(s) CARLSSON ET AL.
	Examiner Rodney P. Swartz, Ph.D.	Art Unit 1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 24 June 2010.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-3,7-33,35-41,47,49,52-54,56,58 and 59 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-3,7-33,35-41,47,49,52-54,56,58 and 59 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsman's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date 6/2010
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

1. Applicants' Response to Office Action, received 24 June 2010, is acknowledged. Claims 1, 7, 28 and 29 have been amended. Claims 5 and 6 have been cancelled.
2. Claims 1-3, 7-33, 35-41, 47, 49, 52-54, 56, 58 and 59 are pending and under consideration.

Rejections Moot or Withdrawn

3. The rejection of claims 5 and 6 under 35 U.S.C. 112, second paragraph, is moot in light of the cancellation of the claims.
4. The rejection of claims 1-3 and 25 under 35 U.S.C. 102(b) as being anticipated by Uhlen et al (*J. Biol. Chem.*, 259(3):1695-1702, 1984), is withdrawn in light of the amendment of the claims.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claim 1-3, 7, 10-12, 14, 16, 17, 21-23 and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Nilsson et al (WO95/19374, 20July1995).

Claims 1-3 are drawn to a polypeptide comprising SEQ ID NO:1 (58 residues) having at least four substitution mutations at positions 13, 14, 28, 32 and 35.

Nilsson et al teach polypeptides (58 residues) comprising instant SEQ ID NO:1 having at least four substitution mutations at positions 13, 14, 28, 32 and 35 (Figure 14).

Claim 7 is the polypeptide of claim 1 further comprising substitution mutations at ≥ 1 of the positions 9, 10, 11, 17, 18, 24, 25 and 27.

The polypeptides of Figure 14 satisfy this further structural limitation.

Claims 10 and 11 are drawn to the polypeptide of claim 1, comprising a substitution mutation at position 28 from asparagine (N) to an amino acid residue selected from arginine (R) and histidine(H).

Polypeptide 5 of Figure 14 satisfies this further limitation.

Claim 12 is drawn to the polypeptide according to claim 1, comprising a substitution mutation at position 32 from glutamine (Q) to arginine (R).

Polypeptide 10 of Figure 14 satisfies this further limitation.

Claim 14 is drawn to the polypeptide according to claim 1, comprising a substitution mutation at position 10 from glutamine (Q) to arginine (R).

Polypeptide 11 of Figure 14 satisfies this further limitation.

Claim 16 is drawn to the polypeptide according to claim 1, comprising a substitution mutation at position 17 from leucine (L) to valine (V).

Polypeptides 4, 5, 9 and 22 of Figure 14 satisfy this further limitation.

Claim 17 is drawn to the polypeptide according to claim 1, comprising a substitution mutation at position 27 from arginine (R) to either lysine (K) or serine (S).

Polypeptides 4, 16, 29 and 31 of Figure 14 satisfy this further limitation.

Claims 21 and 22 are drawn to the polypeptide according to claim 1, in which at least one of the asparagine (N) residues present has been replaced with another amino acid residue.

The polypeptides of Figure 14 satisfy this further limitation with at least one substitution mutation at N11.

Art Unit: 1645

Claim 23 is the polypeptide according to claim 22, comprising at least one mutation, N28A.

Polypeptides 6 and 16 of Figure 14 satisfy this further limitation.

Since the Office does not have the facilities for examining and comparing applicant's polypeptide with the polypeptides of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the protein of the prior art does not possess the same functional characteristics of the claimed protein). See *in re Best*, 562 F.2D 1252, 195 USPQ 430 (CCPA 1977), and *in re Fitzgerald et al.*, 205 USPQ 594.

Thus, in the absence of evidence to the contrary, the polypeptides taught by Nilsson et al which meet the structural criterion of the claims, possess the necessary binding affinity for HER2.

6. The rejection of claims 8, 9, 13, 15, 18-20, 24, 26-33, 35-41, 47, 49, 52-54, 56, 58 and 59 under 35 U.S.C. 112, second paragraph, is maintained for reasons of record.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claim 25 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim depends from a rejected claim.

Conclusion

Art Unit: 1645

8. No claims are allowed.

9. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's Supervisor, Larry Helms, at (571)272-0832.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./

Primary Examiner, Art Unit 1645

September 8, 2010